Owens & Minor (OMI) has disclosed a new risk, in the Regulation category.
Owens & Minor faces significant business risk due to the increasing regulatory oversight of healthcare investments in the U.S. With numerous states enforcing laws that necessitate regulatory clearance or approval for such transactions, the company may encounter delays, increased compliance costs, and potential modifications to their investment strategies. These regulatory challenges could render certain jurisdictions less appealing for healthcare investments, thereby impacting transaction terms and overall investment returns. The situation is further complicated by the possibility of governmental authorities delaying or halting transactions, as highlighted in the Rotech Acquisition risk factor.
Overall, Wall Street has a Moderate Buy consensus rating on OMI stock based on 1 Buy and 2 Holds.
To learn more about Owens & Minor’s risk factors, click here.